DUBLIN–(BUSINESS WIRE)–The “Transdermal Drug Delivery Market Analysis by Applications, by Type, by End user, and by Region – Global Forecast to 2029” report has been added to ResearchAndMarkets.com’s offering.
The transdermal drug delivery market size is estimated to be USD 6.5 billion in 2021 and is expected to witness a CAGR of 6.23% during the forecast period 2022-2029. The rising incidence of chronic diseases and technological improvements in transdermal medication delivery methods are expected to boost the market. Additionally, initiatives by government organizations contributing to the market growth. However, drug failure is expected to hinder the growth.
Segmentation: Transdermal Drug Delivery Market Report 2021-2029
By Application (Revenue, USD Billion)
Hormonal Applications
Central Nervous System Disorders
Pain Management
Cardiovascular Diseases
Others
By Type (Revenue, USD Billion)
Transdermal Semisolids
Transdermal Patches
By End user (Revenue, USD Billion)
Hospitals & Clinics
Home Care Settings
By Region (Revenue, USD Billion)
North America
U.S
Canada
Europe
Germany
France
UK
Spain
Italy
Rest of Europe
Asia Pacific
China
Japan
India
Australia
South Korea
Rest of APAC
Latin America
Brazil
Mexico
Argentina
Rest of LATAM
Middle East & Africa
South Africa
GCC
Rest of MEA
Key Topics Covered:
1. Research Methodology
2. Introduction: Transdermal Drug Delivery
3. Executive Summary
4. Market Dynamics
5. Market Environment Analysis
6. COVID-19 Impact Analysis: Transdermal Drug Delivery Market
7. Market Analysis by Application
8. Market Analysis by Type
9. Market Analysis by End user
10. Regional Market Analysis
11. North America Transdermal Drug Delivery Market
12. Europe Transdermal Drug Delivery Market
13. Asia Pacific Transdermal Drug Delivery Market
14. Latin America Transdermal Drug Delivery Market
15. MEA Transdermal Drug Delivery Market
16. Competitor Analysis
17. Company Profiles
18. Conclusion & Recommendations
Companies Mentioned
Hisamitsu Pharmaceutical (Japan)
Mylan (US)
UCB (Belgium)
Novartis (Switzerland)
GlaxoSmithKline (UK)
Boehringer Ingelheim (Germany)
Johnson & Johnson (US)
Endo International (Ireland)
Purdue Pharma (US).
For more information about this report visit https://www.researchandmarkets.com/r/x8fqla
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
